Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277667 · ClinicalTrials.gov registry record · Phase 3
Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms
A Phase 3 study of Bipolar Disorder, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00277667 is a Phase 3 study of Bipolar Disorder that has completed, run by Lindner Center of HOPE. The registered enrollment target is 40 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00277667, a Phase 3 study of Bipolar Disorder, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the safety, tolerability, and efficacy of quetiapine compared to placebo (sugar pill without medication) in the treatment of bipolar disorder with moderate to severe hypomania or mild mania. Quetiapine is approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar mania.
Conditions Studied
Interventions
- DRUG Quetiapine
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277667
The ClinicalTrials.gov registry entry for NCT00277667 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (88% lower). The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine is the first listed.
NCT00277667 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00277667 about?
NCT00277667 is a clinical study titled "Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms". The purpose of this research study is to evaluate the safety, tolerability, and efficacy of quetiapine compared to placebo (sugar pill without medication) in the treatment of bipolar disorder with moderate to severe hypomania or mild mania. Quetiapine is approved by the United States Food and Drug A...
What is the current status of trial NCT00277667?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2004-02. Estimated completion is 2007-12.
What conditions does trial NCT00277667 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00277667?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00277667?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00277667 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RECRUITING · Phase 3
-
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
COMPLETED · Phase 3
-
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
COMPLETED · Phase 3
-
Acute Treatment of Bipolar II Depression
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.